logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

European News

Daiichi Sankyo and AstraZeneca Announce Global Development and Commercialization Collaboration for Daiichi Sankyo’s HER2 Targeting Antibody Drug Conjugate [Fam-] Trastuzumab Deruxtecan (DS-8201)

• Collaboration combines Daiichi Sankyo’s scientific and technological excellence with AstraZeneca’s global experience and resources in oncology to...

Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase

- Dr. Junichi Koga to become new global Head of Research & Development Unit and Co-Chair of the company's Global Executive Meeting of R&D (GEMRAD),...

Daiichi Sankyo Europe launches mycancertherapy.eu at ESMO 2018

New video-based website on cancer answers most frequently asked patient questions and simplifies medical jargon in 16 (EU & minority) different...

Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio

Intended for US and EU Medical Media Only

- Significant investment in antibody drug conjugate (ADC) manufacturing capabilities will improve research...

World Stroke Day 2016: Research reveals delayed diagnosis leaves atrial fibrillation patients at major stroke risk

• Atrial fibrillation (AF) increases the risk of a severe stroke [1] however almost half of patients are unaware of the risk [2]

• The AFfect survey...

Expert recommendations from the Future of Anticoagulation Report are to be undertaken to improve Atrial Fibrillation management

Management strategies in the new ESC Atrial Fibrillation Guidelines align with those identified in the Report to address the urgent public health...

Daiichi Sankyo Partners With World Thrombosis Day

Promoting awareness of venous thromboembolism and atrial fibrillation, helping to reduce preventable deaths

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Report[1] recommendations aim to improve management of AF as numbers expected to double from 8.8 to 17.9 million adults aged over 55 years between...

Lixiana® (edoxaban) Approved in Switzerland

Daiichi Sankyo’s Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and...

Daiichi Sankyo Master Prize: Award for the Best Graduate in Pharmaceutical Sciences at the University of Munich

Claudia Hildebrandt received the Daiichi Sankyo Master Prize 2014: Award for the best graduate of Pharmaceutical Sciences at the...